Test Price
2,800 AED✅ Home Collection Available
COL2A1 Gene Osteoarthritis with Mild Chondrodysplasia Genetic Test in UAE | 2800 AED | DNA Labs UAE
Executive Summary & Core Metrics
✅ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing
🚚 Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain & VIP Mobile Phlebotomy
📞 Clinical Guidance: Telephonic Post-Test Clinical Result Interpretation Support
💳 Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
This advanced genetic test for the COL2A1 gene using Next-Generation Sequencing (NGS) technology achieves the highest diagnostic accuracy (99.9%) under the supervision of DHA-licensed consultants, with full compliance with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
This Genetic Test analyzes the entire coding region of the COL2A1 gene to identify pathogenic variants linked to early-onset osteoarthritis with mild chondrodysplasia, enabling precise diagnosis and family risk assessment. The assay employs next-generation sequencing with concurrent copy number variant detection for comprehensive molecular evaluation.
| Feature | Our COL2A1 NGS Test | Alternatives (e.g., Single-Gene Sanger) |
|---|---|---|
| Diagnostic Precision | Full gene coverage, 99.9% analytical sensitivity | Limited to known hotspots, ~95% sensitivity |
| Methodology | Next-Generation Sequencing (NGS) with CNV detection | Targeted genotyping or Sanger sequencing of exons 1-54 only |
| Turnaround Time | 3-4 weeks (comprehensive report) | 4-8 weeks for fragment analysis |
| Sample Flexibility | Blood, extracted DNA, or FTA card | Fresh blood only, no dried blood option |
Physician Insight & Safety Protocols
“A genetic diagnosis of COL2A1-related osteoarthritis provides a molecular anchor that transforms vague joint complaints into a targeted management plan. This test offers clarity for patients who have lived with unexplained early-onset arthritis, but it must always be integrated with imaging, clinical examination, and a three-generation pedigree. Our commitment extends beyond the report — we coordinate specialist referrals and genetic counseling to ensure every finding translates into actionable care.”
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory on Medication Continuity
Patients must continue all current medications as prescribed by their treating physician. Genetic results may inform future therapeutic adjustments but never warrant abrupt cessation of anti-inflammatory or analgesic therapies. Consult your rheumatologist before making any changes to your medication regimen.
Patient Safety Exclusion Criteria & Emergency Red Flags
- Exclusion from home collection: Active febrile illness, inability to provide informed consent without a legal guardian, or refusal of mandatory pre-test genetic counseling session.
- Exclusion from result interpretation without counseling: Patients without a documented post-test counseling appointment; minors must have parental consent per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Seek immediate medical attention if: Sudden severe joint swelling, inability to bear weight, signs of acute inflammatory arthritis, or unexpected neurological symptoms — these are not explained by the COL2A1 genotype and require urgent evaluation.
- ER Red Flags: High fever with joint pain, suspected septic arthritis, acute limb deformity.
Patient FAQ & Clinical Guidance
1. What exactly does the COL2A1 gene test detect and why is it important?
The COL2A1 NGS test identifies genetic variants in the collagen type II alpha-1 chain gene that cause early-onset osteoarthritis and mild chondrodysplasia, allowing definitive molecular diagnosis and personalized surveillance. This enables your doctor to differentiate hereditary joint disease from wear-and-tear osteoarthritis and to screen at-risk family members.
2. How should I prepare for the test and what sample is needed?
Preparation requires a mandatory pre-test genetic counseling session to document your clinical history and draw a pedigree chart; the sample can be blood, extracted DNA, or a single drop of blood on an FTA card. No fasting is needed, but you must provide a detailed clinical history of joint symptoms and family history of similar disorders for accurate interpretation.
3. How long until I receive results and what support is available afterward?
Results are delivered within 3 to 4 weeks via secure medical report, and you will receive a telephonic post-test clinical guidance session with a DHA-licensed specialist to interpret the findings and discuss next steps. Genetic counselling referrals and rheumatology coordination are arranged if a pathogenic variant is identified.
4. Will my insurance cover the genetic test and how do I schedule?
Direct billing verification is available via WhatsApp at +971 54 548 8731; coverage depends on your individual plan and medical necessity documentation provided by your referring physician. Our team handles pre-authorization paperwork and coordinates VIP mobile phlebotomy at your preferred time between 8 AM and 11 PM daily.
UAE Regulatory & Data Privacy Adherence
🔒 Compliance Framework
This service is delivered in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All laboratory processes are ISO 9001:2015 certified. DHA Facility License: 1143.
For insurance pre-approval or home collection scheduling (8 AM - 11 PM), contact WhatsApp: +971 54 548 8731
Clinical & Logistical Metadata
| Test Name | COL2A1 Gene Osteoarthritis with Mild Chondrodysplasia Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3-4 Weeks (Comprehensive Report) |
| Sample Type / Matrix | Whole Blood, Extracted DNA, or FTA Card (Dried Blood Spot) |
| Methodology Used | Next-Generation Sequencing (NGS) with Copy Number Variant (CNV) Detection |
| ICD-10-CM Code | M19.90 |
| LOINC Code | 101454-2 |
| DHA Facility License & Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians